MV-CHIK

AXP000208.1 · Vaccine

Platform
measles virus (Schwarz vaccine strain) vector
Targets
CHIKV C-E3-E2-6K-E1
Originator
Institut Pasteur / Themis Bioscience
Sponsor
Merck Sharp & Dohme

Names

NameTypeSource
MV-CHIKpreferred name, codecurator, curator
V184codectgov

Virus

Role
Vaccine vector
Family
Paramyxoviridae
Virus
measles morbillivirus (NCBI Taxonomy 11234)
Strain
Schwarz vaccine strain
Replication
replicating
Modifications
additional transcription unit encoding the chikungunya virus structural proteins C, E3, E2, 6K and E1
Transgenes
CHIKV C, CHIKV E3, CHIKV E2, CHIKV 6K, CHIKV E1
Route
intramuscular
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03807843Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)CompletedPhase 22019-07-162021-05-1341Chikungunya Virus Infection
NCT03635086Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)CompletedPhase 22018-08-222019-01-2560Chikungunya Virus Infection
NCT03101111Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic AreaCompletedPhase 22017-08-092019-04-0234Chikungunya
NCT02861586Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya VaccineCompletedPhase 22016-08-172017-09-01263Chikungunya Virus Infection

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41313671A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults.The Journal of infectious diseases2026name in title: MV-CHIK
PMID 37726181A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial.Vaccine2023name in abstract: MV-CHIK
PMID 34582377Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine.JCI insight2021cited by trial NCT02861586
PMID 31828322Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.The Journal of infectious diseases2020name in abstract: MV-CHIK
PMID 30409443Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.Lancet (London, England)2019cited by trial NCT02861586
PMID 25739878Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.The Lancet. Infectious diseases2015cited by trial NCT03635086

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42506635Mapping Human Clinical Evidence for Chikungunya Vaccines: A Scoping Review of Immunogenicity, Durability, and Safety.Vaccines2026name in abstract: MV-CHIK
PMID 39104592Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.Frontiers in microbiology2024name in abstract: MV-CHIK
PMID 39340001Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis.Vaccines2024name in abstract: MV-CHIK
PMID 39467413Chikungunya vaccine development, challenges, and pathway toward public health impact.Vaccine2024name in abstract: MV-CHIK
PMID 36243743Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.NPJ vaccines2022name in abstract: MV-CHIK
Unconfirmed matches (7)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 42731393NMR relaxation dispersion reveals an order of magnitude range of acid loop motions in protein tyrosine phosphatase 1B.Journal of magnetic resonance (San Diego, Calif. : 1997)2026name in abstract: V184
PMID 38724547Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.Scientific reports2024name in abstract: V184
PMID 19109381Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein.Journal of virology2009name in abstract: V184
PMID 12843079Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.Journal of clinical microbiology2003name in abstract: V184
PMID 21149010The white-rot fungus Pleurotus ostreatus secretes laccase isozymes with different substrate specificities.Mycologia2003name in abstract: V184
PMID 11594690Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes.Antiviral chemistry & chemotherapy2001name in abstract: V184
PMID 9021181Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.Antimicrobial agents and chemotherapy1997name in abstract: V184

Notes

Live recombinant Schwarz-strain measles virus with an extra transcription unit encoding the chikungunya structural polyprotein. Included because a phase 3 trial was authorised and run (Themis, Belgian sites); Merck, which acquired Themis in 2020, later dropped the chikungunya programme. Merck code V184.

How to cite

MV-CHIK (AXP000208.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000208.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.